A Phase 3 interventional study of Emicizumab in Hemophilia A, sponsored by Hoffmann-La Roche. Completed at 72 sites in 24 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.
Among the 22 studies testing emicizumab in Hemophilia A, this one has the largest enrollment, is one of 2 that started in 2017, is one of 11 in phase 3, and was the 5th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Taiwan
Ages 12+ · Men only
Chulalongkorn University · Sites in Thailand
Ages 3–30 · Men only · Healthy volunteers
Bleeding and Clotting Disorders Institute Peoria, Illinois · Sites in United States
Ages 0–90
Indiana Hemophilia &Thrombosis Center, Inc. · Sites in United States
Ages 5–45 · Men only
Versiti Blood Health · Sites in United States
Ages 0–17
By country, each count listing its studies:
emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 13 · Phase 4 6
First in 2015; this study’s year is marked. 2 started in 2017.
This study's enrollment of 195 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 27 across the 22 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
25 studies in Hemophilia A by Hoffmann-La Roche: 5 open now, 8 under way, 4 of them phase 3. Of 15 finished, 12 (80%) have results posted.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2017, is one of 12 in phase 3, and was the 9th registered.
Hoffmann-La Roche’s Hemophilia A studies by the year they started, since 2012.
2 of the studies testing emicizumab in Hemophilia A that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05181618Hoffmann-La RocheA Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis | 2026-11-19 |
| NCT05500807Bleeding and Clotting Disorders Institute Peoria, IllinoisEmicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing emicizumab in Hemophilia A, from their registry updates:
Among Hoffmann-La Roche’s 25 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
This is a phase IIIb, single arm, open-label, multi-center study to evaluate the safety and tolerability of emicizumab in participants with congenital hemophilia A who have documented inhibitors against Factor VIII (FVIII) at enrollment. Approximately 200 participants, aged 12 or older, will be enrolled in this study and are expected to be enrolled at approximately 85 sites globally. Participants will receive an initial weekly dose of prophylactic emicizumab subcutaneously for 4 weeks, followed by a weekly maintenance dose subcutaneously for the remainder of the 2-year treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive initial weekly doses of prophylactic emicizumab subcutaneously for 4 weeks, followed by maintenance doses consisting of half the initial dose, administered subcutaneously for the remainder of the 2-year treatment period
Drug: Emicizumab
Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
Also known as: Hemlibra, RO5534262, ACE910
Overall Summary of the Number of Participants With Adverse Events, Severity Assessed According to the World Health Organization (WHO) Toxicity Grading Scale
Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. aPCC = activated prothrombin complex concentrate
Time frame: From Baseline until study completion (up to 2 years)
Adverse Events (AEs) Rates Per 100 Patient-Years for All-Grade AEs, Serious AEs, and Grade ≥3 AEs
Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. The AE rate per 100 patient-years was computed as follows: AE Rate = (Number of AEs observed/ Total patient-years at risk)\*100. Total patient-years at risk is the sum over all patients of the time intervals (in years) between start of study therapy (study day 1) and the end of follow up.
Time frame: From Baseline until study completion (up to 2 years)
Number of Participants by Hematology and Biochemistry Laboratory Parameter Test Results as Shifts From the WHO Toxicity Grade at Baseline to the Worst WHO Toxicity Grade Post-Baseline
The World Health Organization (WHO) toxicity grading scale was used for determining the severity of laboratory abnormalities (i.e., test results outside of the reference range) for hematology and biochemistry parameters; Grade 0 is normal and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. Baseline was defined as the last available assessment prior to first receipt of study drug. Abs = absolute count; SGOT/AST = aspartate aminotransferase; SGPT/ALT = alanine aminotransferase
Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Change From Baseline in Body Temperature at Specified Timepoints
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Change From Baseline in Systolic Blood Pressure at Specified Timepoints
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Change From Baseline in Diastolic Blood Pressure at Specified Timepoints
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Change From Baseline in Pulse Rate at Specified Timepoints
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Change From Baseline in Respiratory Rate at Specified Timepoints
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Change From Baseline in Body Weight at Specified Timepoints
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Model-Based Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds
The number of bleeds over the efficacy period was analyzed as an ABR using a negative binomial regression model. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all bleed types, bleeds due to surgery/procedure were excluded. Bleeds occurring after dose up-titration have been excluded.
Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all types, bleeds due to surgery/procedure and bleeds occurring after dose up-titration were excluded.
Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all types, bleeds due to surgery/procedure and bleeds occurring after dose up-titration were excluded.
Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Percentage of Participants by the Categorized Number of Bleeds for Treated Bleeds
Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Percentage of Participants by the Categorized Number of Bleeds for All Bleeds
All bleeds: included both treated and non-treated bleeds. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Percentage of Participants by the Categorized Number of Bleeds for Treated Spontaneous Bleeds
Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for Treated Bleeds
The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for All Bleeds
The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds: included both treated and non-treated bleeds. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds
The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Total Score at Specified Timepoints, Adult Participants
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. The Total Score is based on the scores for each domain and ranges from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Total Score at Specified Timepoints
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. The Total Score is based on the scores for each domain and ranges from 0 to 100, with lower scores reflective of better quality of life. An improvement larger than the responder threshold was defined as a decrease from baseline of at least 7 points in the Haem-A-QoL Total score.
Time frame: At 3, 6, 12, and 18 months
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Physical Health Domain Score at Specified Timepoints, Adult Participants
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Physical Health Domain Score at Specified Timepoints
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life. An improvement larger than the responder threshold was defined as a decrease from baseline of at least 10 points in the Haem-A-QoL Physical Health domain score.
Time frame: At 3, 6, 12, and 18 months
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Treatment Domain Score at Specified Timepoints, Adult Participants
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Work and School Domain Score at Specified Timepoints, Adult Participants
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Dealing With Hemophilia Domain Score at Specified Timepoints, Adult Participants
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Feelings Domain Score at Specified Timepoints, Adult Participants
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Family Planning Domain Score at Specified Timepoints, Adult Participants
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Future Domain Score at Specified Timepoints, Adult Participants
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Partnership and Sexuality Domain Score at Specified Timepoints, Adult Participants
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Sports and Leisure Domain Score at Specified Timepoints, Adult Participants
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire View of Yourself Domain Score at Specified Timepoints, Adult Participants
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Total Score at Specified Timepoints, Adolescent Participants
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. The Total Score is derived from the scores for all domains and scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Total Score at Specified Timepoints
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. The Total Score is derived from the scores for all domains and scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life. An improvement larger than the responder threshold was defined as a decrease of at least 5 points in the Haemo-QoL-SF Total score.
Time frame: At 3, 6, 12, and 18 months
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Physical Health Domain Score at Specified Timepoints, Adolescent Participants
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Physical Health Domain Score at Specified Timepoints
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life. An improvement larger than the responder threshold was defined as a decrease of at least 10 points in the Haemo-QoL-SF Physical Health domain score.
Time frame: At 3, 6, 12, and 18 months
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Treatment Domain Score at Specified Timepoints, Adolescent Participants
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Sports and School Domain Score at Specified Timepoints, Adolescent Participants
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Dealing With Hemophilia Domain Score at Specified Timepoints, Adolescent Participants
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Feelings Domain Score at Specified Timepoints, Adolescent Participants
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Family Domain Score at Specified Timepoints, Adolescent Participants
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Friends Domain Score at Specified Timepoints, Adolescent Participants
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Other People Domain Score at Specified Timepoints, Adolescent Participants
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire View of Yourself Domain Score at Specified Timepoints, Adolescent Participants
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the EuroQoL Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) Index Utility Score at Specified Timepoints
The EQ-5D-5L is a generic, self-reported, preference-based health utility measure that consists of six questions and is used to assess health status and inform pharmacoeconomic evaluations. The index utility score is based on the participant's assessment of their health on five scales: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It ranges from -0.224 to 1, with 0 corresponding to death and 1 corresponding to full health; negative values correspond to health states worse than death. Higher scores indicate better quality of life.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Change From Baseline in the EuroQoL Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) Quality-of-Life Visual Analogue Scale (VAS) Score at Specified Timepoints
The EQ-5D-5L is a generic, self-reported, preference-based health utility measure that consists of six questions and is used to assess health status and inform pharmacoeconomic evaluations. The visual analogue scale (VAS) ranges from 0 to 100 points, on which the participant self-assesses their current health status; 0 being the worst health you can imagine and 100 being the best health you can imagine. Higher scores are reflective of better health.
Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Percentage of Participants Who Preferred the New Emicizumab Treatment or the Old Hemophilia Treatment, or Without Treatment Preference, as Assessed by the EmiPref Questionnaire
The EmiPref questionnaire asked participants to specify the treatment they would prefer to continue to receive after receiving treatment with their previous episodic or prophylactic regimen and subcutaneous (SC) emicizumab, or if they had no preference. The 95% confidence intervals were calculated for one sample binomial using the Pearson-Clopper method.
Time frame: Month 3
Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) Against Emicizumab at Anytime Post-Baseline
'Total ADA Negative' is the sum of all subjects who tested negative for ADA in the 2 following categories: 'ADA Negative', those who are pre-dose ADA negative or are missing pre-dose ADA data and who have all negative post-dose ADA results; and 'ADA Negative (Treatment Unaffected)', a subset who are pre-dose ADA positive but do not have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample.
Time frame: Baseline (Week 1), Week 5, and at 3, 6, 9, 12, and 18 months, and at early termination/study completion (up to 24 months)
Mean Trough Plasma Concentrations of Emicizumab at Specified Timepoints
The trough concentration is a measure of the plasma concentration of a study drug at the end of of the dosage interval.
Time frame: Pre-dose at Weeks 2, 3, and 5, Months 3, 6, 12, and 18, and at treatment discontinuation (up to 2 years)
| Milestone | 1.5 mg/kg Emicizumab QW |
|---|---|
| Started | 195 |
| Received at least one dose of emicizumab | 193 |
| Dose up-titrated to 3 mg/kg qw | 2 |
| Completed | 186 |
| Not completed | 9 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Physician decision | 2 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Death | 2 |
Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. aPCC = activated prothrombin complex concentrate
| Participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| Any Adverse Event (AE) | 163 |
| Fatal AE | 2 |
| Serious AE | 31 |
| AE Leading to Withdrawal from Treatment | 1 |
| AE Leading to Dose Modification/Interruption | 4 |
| AE Leading to Study Discontinuation | 1 |
| Grade 3-5 AE | 39 |
| Related AE | 35 |
| Local Injection Site Reaction | 22 |
| Systemic Hypersensitivity/Anaphylac(tic/toid) Reaction | 0 |
| Thromboembolic Event (TE) | 2 |
| TE Related to aPCC and Emicizumab | 0 |
| Thrombotic Microangiopathy (TMA) | 0 |
| TMA Related to aPCC and Emicizumab | 0 |
| Cases of Potential Drug-Induced Liver Injury | 0 |
| Suspected Transmission of Infectious Agent by the Study Drug | 0 |
Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. The AE rate per 100 patient-years was computed as follows: AE Rate = (Number of AEs observed/ Total patient-years at risk)\*100. Total patient-years at risk is the sum over all patients of the time intervals (in years) between start of study therapy (study day 1) and the end of follow up.
| AEs per 100 patient-years | 1.5 mg/kg Emicizumab QW |
|---|---|
| All-Grade AEs | 211.92 (197.49 to 227.13) |
| Serious AEs | 13.25 (9.83 to 17.46) |
| Grade ≥3 AEs | 17.22 (13.29 to 21.95) |
The World Health Organization (WHO) toxicity grading scale was used for determining the severity of laboratory abnormalities (i.e., test results outside of the reference range) for hematology and biochemistry parameters; Grade 0 is normal and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. Baseline was defined as the last available assessment prior to first receipt of study drug. Abs = absolute count; SGOT/AST = aspartate aminotransferase; SGPT/ALT = alanine aminotransferase
| Participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| Hemoglobin, Low - Grade 0 to 0 | 173 |
| Hemoglobin, Low - Grade 0 to 1 | 8 |
| Hemoglobin, Low - Grade 0 to 2 | 4 |
| Hemoglobin, Low - Grade 0 to 4 | 1 |
| Hemoglobin, Low - Grade 1 to 0 | 1 |
| Hemoglobin, Low - Grade 1 to 1 | 2 |
| Hemoglobin, Low - Grade 1 to 2 | 1 |
| Hemoglobin, Low - Grade 1 to 3 | 1 |
| Hemoglobin, Low - Grade 2 to 1 | 1 |
| Hemoglobin, Low - Grade 2 to 3 | 1 |
| Neutrophils, Total (Abs), Low - Grade 0 to 0 | 173 |
| Neutrophils, Total (Abs), Low - Grade 0 to 1 | 13 |
| Neutrophils, Total (Abs), Low - Grade 0 to 2 | 1 |
| Neutrophils, Total (Abs), Low - Grade 0 to 3 | 2 |
| Neutrophils, Total (Abs), Low - Grade 0 to 4 | 2 |
| Neutrophils, Total (Abs), Low - Grade 1 to 1 | 2 |
| Platelets, Low - Grade 0 to 0 | 190 |
| Platelets, Low - Grade 0 to 1 | 2 |
| Platelets, Low - Grade 1 to 0 | 1 |
| Alkaline Phosphatase, High - Grade 0 to 0 | 187 |
| Alkaline Phosphatase, High - Grade 0 to 1 | 3 |
| Alkaline Phosphatase, High - Grade 0 to 2 | 1 |
| Alkaline Phosphatase, High - Grade 1 to 1 | 2 |
| Bilirubin, High - Grade 0 to 0 | 169 |
| Bilirubin, High - Grade 0 to 1 | 14 |
| Bilirubin, High - Grade 1 to 0 | 3 |
| Bilirubin, High - Grade 1 to 1 | 2 |
| Bilirubin, High - Grade 1 to 2 | 3 |
| Bilirubin, High - Grade 2 to 2 | 2 |
| Blood Urea Nitrogen, High - Grade 0 to 0 | 187 |
| Blood Urea Nitrogen, High - Grade 0 to 1 | 5 |
| Blood Urea Nitrogen, High - Grade 1 to 1 | 1 |
| Calcium (Corrected), High - Grade 0 to 0 | 192 |
| Calcium (Corrected), High - Grade 1 to 2 | 1 |
| Calcium (Corrected), Low - Grade 0 to 0 | 173 |
| Calcium (Corrected), Low - Grade 0 to 1 | 15 |
| Calcium (Corrected), Low - Grade 0 to 2 | 1 |
| Calcium (Corrected), Low - Grade 1 to 0 | 3 |
| Calcium (Corrected), Low - Grade 1 to 1 | 1 |
| Creatinine, High - Grade 0 to 0 | 185 |
| Creatinine, High - Grade 0 to 1 | 5 |
| Creatinine, High - Grade 0 to 2 | 1 |
| Creatinine, High - Grade 1 to 1 | 1 |
| Creatinine, High - Grade 1 to 2 | 1 |
| Glucose, High - Grade 0 to 0 | 148 |
| Glucose, High - Grade 0 to 1 | 28 |
| Glucose, High - Grade 0 to 2 | 6 |
| Glucose, High - Grade 1 to 1 | 2 |
| Glucose, High - Grade 1 to 2 | 3 |
| Glucose, High - Grade 2 to 2 | 1 |
| Glucose, High - Grade 2 to 3 | 1 |
| Glucose, High - Grade 3 to 2 | 1 |
| Glucose, High - Grade 3 to 3 | 2 |
| Glucose, High - Grade 4 to 3 | 1 |
| Glucose, Low - Grade 0 to 0 | 180 |
| Glucose, Low - Grade 0 to 1 | 7 |
| Glucose, Low - Grade 0 to 2 | 4 |
| Glucose, Low - Grade 1 to 0 | 2 |
| Magnesium, Low - Grade 0 to 0 | 188 |
| Magnesium, Low - Grade 0 to 1 | 4 |
| Magnesium, Low - Grade 1 to 1 | 1 |
| Phosphorus, Low - Grade 0 to 0 | 160 |
| Phosphorus, Low - Grade 0 to 1 | 21 |
| Phosphorus, Low - Grade 1 to 0 | 2 |
| Phosphorus, Low - Grade 1 to 1 | 9 |
| Phosphorus, Low - Grade 1 to 2 | 1 |
| Potassium, High - Grade 0 to 0 | 189 |
| Potassium, High - Grade 0 to 1 | 2 |
| Potassium, High - Grade 0 to 2 | 1 |
| Potassium, High - Grade 0 to 4 | 1 |
| Potassium, Low - Grade 0 to 0 | 184 |
| Potassium, Low - Grade 0 to 1 | 6 |
| Potassium, Low - Grade 1 to 0 | 3 |
| SGOT/AST, High - Grade 0 to 0 | 164 |
| SGOT/AST, High - Grade 0 to 1 | 13 |
| SGOT/AST, High - Grade 0 to 2 | 8 |
| SGOT/AST, High - Grade 1 to 0 | 1 |
| SGOT/AST, High - Grade 1 to 1 | 5 |
| SGOT/AST, High - Grade 1 to 2 | 1 |
| SGOT/AST, High - Grade 1 to 3 | 1 |
| SGPT/ALT, High - Grade 0 to 0 | 158 |
| SGPT/ALT, High - Grade 0 to 1 | 22 |
| SGPT/ALT, High - Grade 0 to 2 | 5 |
| SGPT/ALT, High - Grade 1 to 0 | 1 |
| SGPT/ALT, High - Grade 1 to 1 | 4 |
| SGPT/ALT, High - Grade 1 to 2 | 2 |
| SGPT/ALT, High - Grade 1 to 4 | 1 |
| Sodium, High - Grade 0 to 0 | 178 |
| Sodium, High - Grade 0 to 1 | 7 |
| Sodium, High - Grade 0 to 2 | 2 |
| Sodium, High - Grade 1 to 0 | 4 |
| Sodium, High - Grade 1 to 1 | 2 |
| Sodium, Low - Grade 0 to 0 | 166 |
| Sodium, Low - Grade 0 to 1 | 19 |
| Sodium, Low - Grade 0 to 2 | 2 |
| Sodium, Low - Grade 1 to 0 | 3 |
| Sodium, Low - Grade 1 to 1 | 2 |
| Sodium, Low - Grade 1 to 2 | 1 |
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
| degrees Celsius | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 36.33 ± 0.52 |
| Change from BL at Week 2 | 0.04 ± 0.41 |
| Change from BL at Week 3 | 0.03 ± 0.40 |
| Change from BL at Week 5 | 0.03 ± 0.45 |
| Change from BL at Month 3 | 0.04 ± 0.45 |
| Change from BL at Month 6 | 0.07 ± 0.50 |
| Change from BL at Month 9 | 0.06 ± 0.48 |
| Change from BL at Month 12 | 0.07 ± 0.48 |
| Change from BL at Month 18 | 0.10 ± 0.53 |
| Change from BL at Early Termination/Study Completion | 0.08 ± 0.48 |
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
| millimetres of mercury (mmHg) | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 121.1 ± 14.3 |
| Change from BL at Week 2 | -0.9 ± 11.1 |
| Change from BL at Week 3 | -1.2 ± 10.6 |
| Change from BL at Week 5 | -1.3 ± 12.3 |
| Change from BL at Month 3 | 0.1 ± 11.5 |
| Change from BL at Month 6 | -0.2 ± 13.1 |
| Change from BL at Month 9 | 0.1 ± 13.1 |
| Change from BL at Month 12 | 0.1 ± 13.9 |
| Change from BL at Month 18 | -0.1 ± 13.8 |
| Change from BL at Early Termination/Study Completion | 1.9 ± 14.1 |
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
| millimetres of mercury (mmHg) | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 75.5 ± 10.4 |
| Change from BL at Week 2 | -1.2 ± 8.5 |
| Change from BL at Week 3 | -1.0 ± 8.9 |
| Change from BL at Week 5 | -1.2 ± 9.2 |
| Change from BL at Month 3 | -0.3 ± 9.8 |
| Change from BL at Month 6 | -0.7 ± 10.1 |
| Change from BL at Month 9 | -1.3 ± 9.4 |
| Change from BL at Month 12 | -1.2 ± 10.4 |
| Change from BL at Month 18 | -0.9 ± 9.6 |
| Change from BL at Early Termination/Study Completion | 0.0 ± 11.0 |
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
| beats per minute | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 76.6 ± 11.6 |
| Change from BL at Week 2 | 1.0 ± 9.9 |
| Change from BL at Week 3 | 1.6 ± 11.6 |
| Change from BL at Week 5 | -0.5 ± 11.3 |
| Change from BL at Month 3 | -0.8 ± 10.4 |
| Change from BL at Month 6 | -0.7 ± 11.6 |
| Change from BL at Month 9 | -1.0 ± 11.3 |
| Change from BL at Month 12 | -0.5 ± 12.2 |
| Change from BL at Month 18 | -2.1 ± 12.7 |
| Change from BL at Early Termination/Study Completion | -1.2 ± 11.9 |
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
| breaths per minute | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 17.0 ± 3.1 |
| Change from BL at Week 2 | 0.2 ± 2.2 |
| Change from BL at Week 3 | 0.0 ± 2.3 |
| Change from BL at Week 5 | -0.1 ± 2.5 |
| Change from BL at Month 3 | 0.3 ± 4.7 |
| Change from BL at Month 6 | -0.1 ± 2.5 |
| Change from BL at Month 9 | 0.0 ± 2.7 |
| Change from BL at Month 12 | 0.3 ± 2.9 |
| Change from BL at Month 18 | -0.4 ± 2.7 |
| Change from BL at Early Termination/Study Completion | -0.7 ± 3.1 |
Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.
| kilograms (kg) | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 69.55 ± 16.60 |
| Change from BL at Week 2 | 0.14 ± 1.06 |
| Change from BL at Week 3 | 0.34 ± 1.18 |
| Change from BL at Week 5 | 0.52 ± 1.56 |
| Change from BL at Month 3 | 0.98 ± 2.44 |
| Change from BL at Month 6 | 1.11 ± 3.20 |
| Change from BL at Month 9 | 1.61 ± 4.08 |
| Change from BL at Month 12 | 1.85 ± 4.88 |
| Change from BL at Month 18 | 2.58 ± 5.56 |
| Change from BL at Early Termination/Study Completion | 3.15 ± 6.78 |
The number of bleeds over the efficacy period was analyzed as an ABR using a negative binomial regression model. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all bleed types, bleeds due to surgery/procedure were excluded. Bleeds occurring after dose up-titration have been excluded.
| bleeds per year | 1.5 mg/kg Emicizumab QW |
|---|---|
| Treated Bleeds | 0.5 (0.27 to 0.89) |
| All Bleeds | 1.1 (0.80 to 1.47) |
| Treated Joint Bleeds | 0.4 (0.15 to 0.86) |
| Treated Target Joint Bleeds | 0.2 (0.07 to 0.68) |
| Treated Spontaneous Bleeds | 0.3 (0.15 to 0.73) |
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all types, bleeds due to surgery/procedure and bleeds occurring after dose up-titration were excluded.
| bleeds per year | 1.5 mg/kg Emicizumab QW |
|---|---|
| Treated Bleeds | 0.6 (0.00 to 4.85) |
| All Bleeds | 1.3 (0.06 to 6.02) |
| Treated Joint Bleeds | 0.4 (0.00 to 4.55) |
| Treated Target Joint Bleeds | 0.3 (0.00 to 4.28) |
| Treated Spontaneous Bleeds | 0.4 (0.00 to 4.49) |
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all types, bleeds due to surgery/procedure and bleeds occurring after dose up-titration were excluded.
| bleeds per year | 1.5 mg/kg Emicizumab QW |
|---|---|
| Treated Bleeds | 0.0 (0.00 to 0.00) |
| All Bleeds | 0.0 (0.00 to 1.01) |
| Treated Joint Bleeds | 0.0 (0.00 to 0.00) |
| Treated Target Joint Bleeds | 0.0 (0.00 to 0.00) |
| Treated Spontaneous Bleeds | 0.0 (0.00 to 0.00) |
Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
| Percentage of participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| 0 Bleeds | 82.6 (76.5 to 87.6) |
| 1-3 Bleeds | 12.3 (8.0 to 17.8) |
| 4-10 Bleeds | 4.1 (1.8 to 7.9) |
| >10 Bleeds | 1.0 (0.1 to 3.7) |
All bleeds: included both treated and non-treated bleeds. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
| Percentage of participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| 0 Bleeds | 54.9 (47.6 to 62.0) |
| 1-3 Bleeds | 30.3 (23.9 to 37.2) |
| 4-10 Bleeds | 12.3 (8.0 to 17.8) |
| >10 Bleeds | 2.6 (0.8 to 5.9) |
Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
| Percentage of participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| 0 Bleeds | 89.2 (84.0 to 93.2) |
| 1-3 Bleeds | 8.7 (5.2 to 13.6) |
| 4-10 Bleeds | 1.5 (0.3 to 4.4) |
| >10 Bleeds | 0.5 (0.0 to 2.8) |
The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
| Percentage of participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| ABR <1 | 90.3 (85.2 to 94.0) |
| ABR 1-3.4 | 6.2 (3.2 to 10.5) |
| ABR 3.5-10 | 2.6 (0.8 to 5.9) |
| ABR >10 | 1.0 (0.1 to 3.7) |
The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds: included both treated and non-treated bleeds. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
| Percentage of participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| ABR <1 | 72.3 (65.5 to 78.5) |
| ABR 1-3.4 | 20.5 (15.1 to 26.9) |
| ABR 3.5-10 | 4.6 (2.1 to 8.6) |
| ABR >10 | 2.6 (0.8 to 5.9) |
The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.
| Percentage of participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| ABR <1 | 95.4 (91.4 to 97.9) |
| ABR 1-3.4 | 2.6 (0.8 to 5.9) |
| ABR 3.5-10 | 1.0 (0.1 to 3.7) |
| ABR >10 | 1.0 (0.1 to 3.7) |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. The Total Score is based on the scores for each domain and ranges from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 41.09 ± 16.15 |
| Change from BL at Month 3 | -17.39 ± 12.86 |
| Change from BL at Month 6 | -16.40 ± 14.58 |
| Change from BL at Month 12 | -17.44 ± 14.16 |
| Change from BL at Month 18 | -16.27 ± 15.39 |
| Change from BL at Early Termination/Study Completion | -14.13 ± 13.70 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. The Total Score is based on the scores for each domain and ranges from 0 to 100, with lower scores reflective of better quality of life. An improvement larger than the responder threshold was defined as a decrease from baseline of at least 7 points in the Haem-A-QoL Total score.
| Percentage of participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| Month 3 | 78.2 |
| Month 6 | 72.4 |
| Month 12 | 70.8 |
| Month 18 | 69.9 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 51.13 ± 23.02 |
| Change from BL at Month 3 | -27.36 ± 20.70 |
| Change from BL at Month 6 | -26.10 ± 23.12 |
| Change from BL at Month 12 | -25.21 ± 23.31 |
| Change from BL at Month 18 | -23.14 ± 24.51 |
| Change from BL at Early Termination/Study Completion | -23.29 ± 25.16 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life. An improvement larger than the responder threshold was defined as a decrease from baseline of at least 10 points in the Haem-A-QoL Physical Health domain score.
| Percentage of participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| Month 3 | 79.6 |
| Month 6 | 74.5 |
| Month 12 | 72.9 |
| Month 18 | 71.3 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 39.40 ± 19.89 |
| Change from BL at Month 3 | -23.44 ± 22.07 |
| Change from BL at Month 6 | -21.01 ± 23.74 |
| Change from BL at Month 12 | -22.21 ± 22.57 |
| Change from BL at Month 18 | -20.34 ± 25.37 |
| Change from BL at Early Termination/Study Completion | -21.16 ± 22.31 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 39.23 ± 25.31 |
| Change from BL at Month 3 | -21.40 ± 26.51 |
| Change from BL at Month 6 | -21.91 ± 27.17 |
| Change from BL at Month 12 | -22.43 ± 25.55 |
| Change from BL at Month 18 | -21.43 ± 26.65 |
| Change from BL at Early Termination/Study Completion | -18.83 ± 29.54 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 26.61 ± 19.76 |
| Change from BL at Month 3 | 5.32 ± 30.06 |
| Change from BL at Month 6 | 5.73 ± 28.14 |
| Change from BL at Month 12 | 5.24 ± 29.18 |
| Change from BL at Month 18 | 7.70 ± 29.75 |
| Change from BL at Early Termination/Study Completion | 10.60 ± 33.42 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 36.25 ± 24.53 |
| Change from BL at Month 3 | -21.22 ± 22.69 |
| Change from BL at Month 6 | -20.88 ± 24.11 |
| Change from BL at Month 12 | -22.37 ± 23.78 |
| Change from BL at Month 18 | -19.55 ± 25.43 |
| Change from BL at Early Termination/Study Completion | -17.95 ± 23.62 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 25.64 ± 28.49 |
| Change from BL at Month 3 | -8.64 ± 20.95 |
| Change from BL at Month 6 | -9.07 ± 20.78 |
| Change from BL at Month 12 | -10.83 ± 22.51 |
| Change from BL at Month 18 | -12.39 ± 25.20 |
| Change from BL at Early Termination/Study Completion | -9.38 ± 24.81 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 42.70 ± 21.95 |
| Change from BL at Month 3 | -15.56 ± 17.63 |
| Change from BL at Month 6 | -15.46 ± 17.83 |
| Change from BL at Month 12 | -14.46 ± 20.10 |
| Change from BL at Month 18 | -14.43 ± 19.83 |
| Change from BL at Early Termination/Study Completion | -13.29 ± 19.56 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 23.17 ± 28.65 |
| Change from BL at Month 3 | -7.35 ± 25.25 |
| Change from BL at Month 6 | -6.03 ± 22.76 |
| Change from BL at Month 12 | -7.74 ± 27.60 |
| Change from BL at Month 18 | -9.72 ± 28.16 |
| Change from BL at Early Termination/Study Completion | -4.05 ± 21.32 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 68.86 ± 21.24 |
| Change from BL at Month 3 | -19.65 ± 23.67 |
| Change from BL at Month 6 | -17.63 ± 25.86 |
| Change from BL at Month 12 | -22.56 ± 22.17 |
| Change from BL at Month 18 | -20.20 ± 25.86 |
| Change from BL at Early Termination/Study Completion | -20.65 ± 28.65 |
The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 43.57 ± 22.05 |
| Change from BL at Month 3 | -13.51 ± 20.63 |
| Change from BL at Month 6 | -15.04 ± 21.19 |
| Change from BL at Month 12 | -15.71 ± 19.88 |
| Change from BL at Month 18 | -15.19 ± 21.88 |
| Change from BL at Early Termination/Study Completion | -9.50 ± 20.70 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. The Total Score is derived from the scores for all domains and scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 35.10 ± 12.42 |
| Change from BL at Month 3 | -9.60 ± 12.51 |
| Change from BL at Month 6 | -12.65 ± 12.72 |
| Change from BL at Month 12 | -13.57 ± 13.20 |
| Change from BL at Month 18 | -14.02 ± 11.83 |
| Change from BL at Early Termination/Study Completion | -18.37 ± 17.53 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. The Total Score is derived from the scores for all domains and scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life. An improvement larger than the responder threshold was defined as a decrease of at least 5 points in the Haemo-QoL-SF Total score.
| Percentage of participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| Month 3 | 63.9 |
| Month 6 | 75.7 |
| Month 12 | 75.0 |
| Month 18 | 69.2 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 42.14 ± 18.40 |
| Change from BL at Month 3 | -29.10 ± 20.12 |
| Change from BL at Month 6 | -29.78 ± 17.55 |
| Change from BL at Month 12 | -30.47 ± 20.74 |
| Change from BL at Month 18 | -30.71 ± 18.83 |
| Change from BL at Early Termination/Study Completion | -34.03 ± 25.66 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life. An improvement larger than the responder threshold was defined as a decrease of at least 10 points in the Haemo-QoL-SF Physical Health domain score.
| Percentage of participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| Month 3 | 77.8 |
| Month 6 | 78.4 |
| Month 12 | 75.0 |
| Month 18 | 79.5 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 31.61 ± 18.12 |
| Change from BL at Month 3 | -9.38 ± 20.94 |
| Change from BL at Month 6 | -8.64 ± 23.23 |
| Change from BL at Month 12 | -10.74 ± 21.31 |
| Change from BL at Month 18 | -12.68 ± 21.68 |
| Change from BL at Early Termination/Study Completion | -20.83 ± 23.87 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 62.32 ± 21.30 |
| Change from BL at Month 3 | -15.82 ± 25.55 |
| Change from BL at Month 6 | -20.04 ± 29.27 |
| Change from BL at Month 12 | -22.07 ± 26.71 |
| Change from BL at Month 18 | -28.21 ± 27.80 |
| Change from BL at Early Termination/Study Completion | -23.61 ± 28.16 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 24.11 ± 14.79 |
| Change from BL at Month 3 | -7.23 ± 18.25 |
| Change from BL at Month 6 | -7.72 ± 17.75 |
| Change from BL at Month 12 | -10.35 ± 20.24 |
| Change from BL at Month 18 | -3.39 ± 25.70 |
| Change from BL at Early Termination/Study Completion | -12.50 ± 23.48 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 26.43 ± 25.10 |
| Change from BL at Month 3 | -9.57 ± 20.08 |
| Change from BL at Month 6 | -16.36 ± 21.54 |
| Change from BL at Month 12 | -13.09 ± 22.80 |
| Change from BL at Month 18 | -15.18 ± 25.51 |
| Change from BL at Early Termination/Study Completion | -23.96 ± 32.67 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 46.07 ± 20.79 |
| Change from BL at Month 3 | -6.84 ± 15.66 |
| Change from BL at Month 6 | -11.95 ± 20.84 |
| Change from BL at Month 12 | -14.84 ± 23.32 |
| Change from BL at Month 18 | -15.36 ± 21.67 |
| Change from BL at Early Termination/Study Completion | -15.28 ± 19.08 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 35.95 ± 26.02 |
| Change from BL at Month 3 | -0.52 ± 24.95 |
| Change from BL at Month 6 | -3.19 ± 28.13 |
| Change from BL at Month 12 | -5.47 ± 27.57 |
| Change from BL at Month 18 | -5.95 ± 36.41 |
| Change from BL at Early Termination/Study Completion | -7.41 ± 31.56 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 21.43 ± 17.50 |
| Change from BL at Month 3 | -2.93 ± 18.72 |
| Change from BL at Month 6 | -5.51 ± 19.08 |
| Change from BL at Month 12 | -8.01 ± 18.53 |
| Change from BL at Month 18 | -6.79 ± 17.51 |
| Change from BL at Early Termination/Study Completion | -11.81 ± 18.55 |
The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 26.07 ± 22.04 |
| Change from BL at Month 3 | -2.73 ± 26.03 |
| Change from BL at Month 6 | -8.27 ± 23.27 |
| Change from BL at Month 12 | -5.08 ± 24.82 |
| Change from BL at Month 18 | -5.89 ± 21.54 |
| Change from BL at Early Termination/Study Completion | -13.19 ± 26.59 |
The EQ-5D-5L is a generic, self-reported, preference-based health utility measure that consists of six questions and is used to assess health status and inform pharmacoeconomic evaluations. The index utility score is based on the participant's assessment of their health on five scales: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It ranges from -0.224 to 1, with 0 corresponding to death and 1 corresponding to full health; negative values correspond to health states worse than death. Higher scores indicate better quality of life.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 0.67 ± 0.23 |
| Change from BL at Month 3 | 0.08 ± 0.18 |
| Change from BL at Month 6 | 0.11 ± 0.18 |
| Change from BL at Month 12 | 0.09 ± 0.19 |
| Change from BL at Month 18 | 0.07 ± 0.21 |
| Change from BL at Early Termination/Study Completion | 0.10 ± 0.22 |
The EQ-5D-5L is a generic, self-reported, preference-based health utility measure that consists of six questions and is used to assess health status and inform pharmacoeconomic evaluations. The visual analogue scale (VAS) ranges from 0 to 100 points, on which the participant self-assesses their current health status; 0 being the worst health you can imagine and 100 being the best health you can imagine. Higher scores are reflective of better health.
| score on a scale | 1.5 mg/kg Emicizumab QW |
|---|---|
| Baseline (BL) - Value at Visit | 71.01 ± 19.41 |
| Change from BL at Month 3 | 8.02 ± 18.70 |
| Change from BL at Month 6 | 10.27 ± 17.24 |
| Change from BL at Month 12 | 10.69 ± 18.18 |
| Change from BL at Month 18 | 9.49 ± 21.08 |
| Change from BL at Early Termination/Study Completion | 14.52 ± 17.91 |
The EmiPref questionnaire asked participants to specify the treatment they would prefer to continue to receive after receiving treatment with their previous episodic or prophylactic regimen and subcutaneous (SC) emicizumab, or if they had no preference. The 95% confidence intervals were calculated for one sample binomial using the Pearson-Clopper method.
| Percentage of participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| Prefer the New Study Drug Treatment (Emicizumab) | 96.6 (92.85 to 98.76) |
| Prefer my Old Hemophilia Treatment | 0.6 (0.01 to 3.07) |
| Have no Preference | 2.8 (0.91 to 6.40) |
'Total ADA Negative' is the sum of all subjects who tested negative for ADA in the 2 following categories: 'ADA Negative', those who are pre-dose ADA negative or are missing pre-dose ADA data and who have all negative post-dose ADA results; and 'ADA Negative (Treatment Unaffected)', a subset who are pre-dose ADA positive but do not have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample.
| Participants | 1.5 mg/kg Emicizumab QW |
|---|---|
| Total ADA Negative (Neg + Neg Unaffected) | 183 |
| ADA Negative | 180 |
| ADA Negative (Treatment Unaffected) | 3 |
| Total ADA Positive (Boosted + Induced) | 10 |
| ADA Positive (Treatment Boosted) | 2 |
| ADA Positive (Treatment Induced) | 8 |
The trough concentration is a measure of the plasma concentration of a study drug at the end of of the dosage interval.
| micrograms per millilitre (μg/mL) | 1.5 mg/kg Emicizumab QW |
|---|---|
| Week 2 | 16.7 ± 5.5 |
| Week 3 | 30.7 ± 9.2 |
| Week 5 | 52.4 ± 15.5 |
| Month 3 | 52.5 ± 18.3 |
| Month 6 | 53.4 ± 19.3 |
| Month 12 | 54.2 ± 20.6 |
| Month 18 | 53.6 ± 18.3 |
| Treatment Discontinuation | 54.6 ± 19.0 |
Collected over From Baseline until study completion (up to 2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.5 mg/kg Emicizumab QW | 2/193 (1%) | 31/193 (16.1%) | 104/193 (53.9%) |
| Event | 1.5 mg/kg Emicizumab QW |
|---|---|
| CATHETER SITE ABSCESSInfections and infestations | 2/193 |
| FEMUR FRACTUREInjury, poisoning and procedural complications | 2/193 |
| WOUND DEHISCENCEInjury, poisoning and procedural complications | 2/193 |
| HAEMATOMA MUSCLEMusculoskeletal and connective tissue disorders | 2/193 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 1/193 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 1/193 |
| ABDOMINAL COMPARTMENT SYNDROMEGastrointestinal disorders | 1/193 |
| DIVERTICULUM INTESTINAL HAEMORRHAGICGastrointestinal disorders | 1/193 |
| GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 1/193 |
| RETROPERITONEAL HAEMATOMAGastrointestinal disorders | 1/193 |
| Event | 1.5 mg/kg Emicizumab QW |
|---|---|
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 33/193 |
| NASOPHARYNGITISInfections and infestations | 30/193 |
| HEADACHENervous system disorders | 29/193 |
| INJECTION SITE REACTIONGeneral disorders | 22/193 |
| PYREXIAGeneral disorders | 21/193 |
| INFLUENZAInfections and infestations | 16/193 |
| FALLInjury, poisoning and procedural complications | 12/193 |
| COUGHRespiratory, thoracic and mediastinal disorders | 12/193 |
| LIMB INJURYInjury, poisoning and procedural complications | 10/193 |
| Age, Continuous(Years) | 1.5 mg/kg Emicizumab QW |
|---|---|
| Mean | 32.2 ± 16.6 |
| Age, Customized(Participants) | 1.5 mg/kg Emicizumab QW |
|---|---|
| ≥12 to <18 Years Old | 40 |
| ≥18 to <65 Years Old | 146 |
| ≥65 Years Old | 9 |
| Sex: Female, Male(Participants) | 1.5 mg/kg Emicizumab QW |
|---|---|
| Female | 0 |
| Male | 195 |
| Ethnicity (NIH/OMB)(Participants) | 1.5 mg/kg Emicizumab QW |
|---|---|
| Hispanic or Latino | 41 |
| Not Hispanic or Latino | 143 |
| Unknown or Not Reported | 11 |
| Race (NIH/OMB)(Participants) | 1.5 mg/kg Emicizumab QW |
|---|---|
| American Indian or Alaska Native | 19 |
| Asian | 38 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 7 |
| White | 121 |
| More than one race | 0 |
| Unknown or Not Reported | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2017 to primary completion in Nov 2020, 38 months.
Results were first posted in Jun 2021, 6 months after primary completion.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 38 months is above that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emicizumab